PhaseBio Pharmaceuticals
CompanyUnited States
PhaseBio Pharmaceuticals develops 3 assets, the furthest in phase 3 (bentracimab in hemorrhage). Mostly antibody and protein or enzyme acting on CYP11B2; based in the United States.
- 3
- Assets
- Furthest stage
- Phase 3
- Raised
- $95.5M
- 2
- Trials
- 0
- Signals
Pipeline
3Binds ticagrelor and its active metabolite to reverse antiplatelet activity.
Phase 3, Antibody, hemorrhage, invasive procedure
Long-acting GLP-1 receptor agonist fusion protein that stimulates glucose-dependent insulin secretion and improves glycemic control.
Phase 2, no development reported, Protein or enzyme, type 2 diabetes
Selectively inhibits aldosterone synthase to reduce aldosterone production and lower blood pressure.
Preclinical, no development reported, Small molecule, CYP11B2, treatment-resistant hypertension
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials2
- Funding rounds and grants3
- Deals10
- Similar companies6